STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. Insider Trading Activity

BeOne Medicines (ONC) SVP exercises options and sells ADS under plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share. He acquired American Depositary Shares at prices of $194.47, $213.32 and $159.03 per ADS, and sold 1,669 ADS at $325 pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. After these transactions he held 338,884 ordinary shares directly.

Positive

  • None.

Negative

  • None.
Insider Lee Chan Henry
Role SVP, General Counsel
Sold 1,669 shs ($542K)
Approx. gross sale proceeds $542K
Approx. exercise cost $320K
Type Security Shares Price Value
Exercise Share Option (Right to Buy) F3, F4 6,682 $0.00 $0.00
Exercise Share Option (Right to Buy) F3, F5 8,645 $0.00 $0.00
Exercise Share Option (Right to Buy) F3, F6 6,370 $0.00 $0.00
Exercise American Depositary Shares F1 514 $194.47 $100K
Exercise American Depositary Shares F1 665 $213.32 $142K
Exercise American Depositary Shares F1 490 $159.03 $78K
Sale American Depositary Shares F1, F2 1,669 $325.00 $542K
holding Ordinary Shares -- -- --
Holdings After Transaction: Share Option (Right to Buy) — 180,609 shares (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 338,884 shares (Direct)
Footnotes (6)
  1. F1. Each American Depositary Share represents 13 Ordinary Shares.
  2. F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
  3. F3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
  4. F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
  5. F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
  6. F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Options exercised 21,697 ordinary shares Total underlying ordinary shares from option exercises on 2026-07-22
Option exercise prices $14.96; $16.41; $12.23 per share Exercise prices of Share Options (Right to Buy) converted into ordinary shares
ADS acquired 514 ADS at $194.47; 665 ADS at $213.32; 490 ADS at $159.03 American Depositary Shares acquired in connection with derivative exercises on 2026-07-22
ADS sold 1,669 ADS at $325.00 per ADS Sale of American Depositary Shares on 2026-07-22 under Rule 10b5-1 trading plan
Post-transaction holdings 338,884 ordinary shares Directly owned ordinary shares after the reported July 22, 2026 transactions
ADS to ordinary share ratio 1 ADS = 13 Ordinary Shares Each American Depositary Share represents 13 Ordinary Shares
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
American Depositary Shares financial
"Each American Depositary Share represents 13 Ordinary Shares."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Share Option (Right to Buy) financial
"The security title for derivative entries is reported as Share Option (Right to Buy)."
accelerated vesting financial
"Unvested securities are subject to accelerated vesting upon certain termination events."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?
Lee Chan Henry, BeOne Medicines’ SVP and general counsel, exercised options on 21,697 ordinary shares and acquired American Depositary Shares at several prices, then sold 1,669 ADS at $325 each. All reported transactions occurred on July 22, 2026, in his direct ownership account.

Were the BeOne Medicines (ONC) insider sales made under a Rule 10b5-1 plan?
Yes. The sale of 1,669 American Depositary Shares at $325 per ADS was effected under a Rule 10b5-1 trading plan adopted by Lee Chan Henry on May 29, 2026, indicating the sale followed a pre-arranged trading schedule rather than discretionary timing.

How many BeOne Medicines (ONC) shares does Lee Chan Henry own after these transactions?
After the reported option exercises and ADS transactions, Lee Chan Henry directly owns 338,884 ordinary shares of BeOne Medicines Ltd. This figure reflects his ordinary share position following the July 22, 2026 activity and is reported as direct ownership in the filing.

What option exercises did the BeOne Medicines (ONC) executive complete?
On July 22, 2026, Lee Chan Henry exercised options covering 21,697 ordinary shares at exercise prices of $14.96, $16.41 and $12.23 per share. These options were reported as Share Options (Right to Buy) with expiration dates in 2032, 2033 and 2034, respectively.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Chan Henry
(Last)(First)(Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL4051
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares338,884D
American Depositary Shares(1)07/22/2026M514A$194.47514D
American Depositary Shares(1)07/22/2026M665A$213.321,179D
American Depositary Shares(1)07/22/2026M490A$159.031,669D
American Depositary Shares(1)07/22/2026S(2)1,669D$3250D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$14.96(3)07/22/2026M6,682 (4)08/04/2032Ordinary Shares6,682$010,556D
Share Option (Right to Buy)$16.41(3)07/22/2026M8,645 (5)06/14/2033Ordinary Shares8,645$071,123D
Share Option (Right to Buy)$12.23(3)07/22/2026M6,370 (6)06/04/2034Ordinary Shares6,370$098,930D
Explanation of Responses:
1. Each American Depositary Share represents 13 Ordinary Shares.
2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Remarks:
/s/ Chan Henry Lee07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR